Trial · NCT03902184
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
NCT03902184, Phase 2, Completed, Innate Pharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma. Trials, record NCT03902184. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03902184
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
- NCT number
- NCT03902184
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 170 participants, actual
- Lead sponsor
- Innate Pharma
- Conditions
- Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
- Interventions
- IPH4102
- First posted
- 2019-04-03
- Last updated
- 2026-04-29
- Other registries' IDs
- eudract:2018-003969-33
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | From the first dose until study completion, an expected average of 2 years | Using the Olsen (2011, JCO) criteria (All cohorts) |
| Secondary | Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (All cohorts) | From first dose until study completion, an expected average of 2 years | patients with treatment-related adverse events as assessed by CTCAE v5.0 |
| Secondary | Quality of life (QoL) (All cohorts) | Through study completion, an expected average of 2 years | Using the Skindex29 questionnaire to assesse the effects of skin disease on quality of life in three domains: Symptoms, Emotions, and Functioning |
| Secondary | pruritus (All cohorts) | Through study completion, an expected average of 2 years | Using Visual Analog Scale (VAS) for prutitus assessment: From 0 = No pruritus to 10 = Pruritus as bad as it could possibly be |
| Secondary | ORR using blinded central review (Cohort 1) | From the first dose until study completion, an expected average of 2 years | Using the Olsen (2011, JCO) criteria |
| Secondary | Progression free survival (PFS) (All cohorts) | From the first dose until study completion, an expected average of 2 years | Will be evaluated using the Kaplan-Meier method |
| Secondary | Overall survival (OS) (All cohorts) | From the first dose until study completion, an expected average of 2 years | Will be evaluated using the Kaplan-Meier method |
| Secondary | PK parameters : Maximum Plasma Concentration of IPH4102 alone (All cohorts) | From the first dose until study completion, an expected average of 2 years | Maximum Plasma Concentration (Cmax) (W1, W5) |
| Secondary | PK parameters :Trough Concentration of IPH4102 alone (All cohorts) | From the first dose until study completion, an expected average of 2 years | Trough Concentration (Ctrough) every 8 or 12 weeks |
| Secondary | Immunogenicity of IPH4102 alone (All cohorts) | From the first dose until study completion, an expected average of 2 years | A serum sample will be collected at the specified time points for evaluation of anti-drug antibodies (ADA). |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03902184
GET https://conductscience.org/api/trials/v1/NCT03902184/registered